Cytek Biosciences, Inc. (CTKB) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$5.27

From 52W high−13.79%

Volume700546.00

Market cap$682.41M

P/E (TTM)—

P/S (TTM)3.3x

Div yield—

Key dataOct 19, 2026

Open

$5.27

From 52W high

−13.79%

Volume

700546.00

Market cap

$682.41M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−16.5x

P/E (TTM)

—

RSI (14)

46.4

MomentumView details →

1D Return

+0.00%

YTD Return

+3.56%

SummaryUpdated Jun 1, 2026

Cytek Biosciences, Inc. (NASDAQ:CTKB) is a cell analysis solutions company founded in 1992 and headquartered in Fremont, California. Originally known as Cytoville, Inc., the company changed its name to Cytek Biosciences in August 2015 and went public in July 2021. Cytek specializes in developing and manufacturing advanced flow cytometry instruments and related products that enable researchers and clinicians to analyze individual cells with unprecedented precision and detail. The company has established itself as a pioneer in <b>Full Spectrum Profiling (FSP)</b> technology, which represents a significant advancement over conventional flow cytometry methods used in biomedical research and clinical applications.

Ask drillr about Cytek Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−16.5x

EV/Sales

2.2x

P/S (TTM)

3.3x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

53.23%

Net Margin

−38.98%

EBITDA Margin

−13.14%

ROE (TTM)

−25.03%

ROA (TTM)

−18.03%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+5.44%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+7.10%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

+3.56%

1Y Return

+29.46%

RSI (14)

46.4

vs 50D SMA

+2.91%

vs 200D SMA

+12.79%

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

4.48x

Quick Ratio

3.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.05

EPS Surprise

46.43%

Beats (12Q)

7/12

Next Q EPS Est

−$0.02

Avg Surprise (4Q)

−13.39%

Rev Surprise

1.76%

Financials snapshotView financials →

Revenue (TTM)

206.71M

Net Income (TTM)

−80.58M

Op. CF (TTM)

−6.04M

Next earningsNov 4, 2026 →

Latest newsMore news →

Cytek Biosciences launched a new Cloud Analysis tool within its Cytek Cloud digital ecosystem, expanding its end-to-end flow cytometry platform.26d ago

Sysmex Europe and Cytek Biosciences announced a collaboration to expand access to advanced clinical flow cytometry.40d ago

Similar companies

Gaush Meditech Ltd02407.HK Anteris Technologies Global Corp.AVR Varex Imaging CorporationVREX AdaptHealth Corp.AHCO OrthoPediatrics Corp.KIDS InMode Ltd.INMD Find similar companies →

Latest newsMore news →

Cytek Biosciences launched a new Cloud Analysis tool within its Cytek Cloud digital ecosystem, expanding its end-to-end flow cytometry platform.26d ago Sysmex Europe and Cytek Biosciences announced a collaboration to expand access to advanced clinical flow cytometry.40d ago A jury in the U.S. District Court for the District of Delaware ruled in favor of Cytek Biosciences on three of four patent claims asserted by Beckman Coulter, finding noninfringement and invalidity, but found infringement under the doctrine of equivalents on one claim and awarded $56 million in damages.59d ago